Featured Studies Results
Study of a New InvestigationaI Inhibitor to Treat People with Advanced Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/300/study-of-a-new-investigationai-inhibitor-to-treat-people-with-advanced-solid-tumors
Clinicaltrials.gov identifier:
NCT05932862 (https://clinicaltrials.gov/show/NCT05932862)
Treatment
Treatment study for people with advanced solid tumors
The Experience of Genetic Testing Among Latinas with a BRCA1 or BRCA2 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/305/the-experience-of-genetic-testing-among-latinas-with-a-brca1-or-brca2-mutation
Surveys, Registries, Interviews
Interviews with Latinas who have a BRCA1 or BRCA2 mutation
PreCharge: Digital Program for People Affected by Hereditary Cancer
https://www.facingourrisk.org/research-clinical-trials/study/292/precharge-digital-program-for-people-with-hereditary-cancer-syndromes
Quality of Life
Study to help people affected by hereditary cancer and who have not been diagnosed with cancer improve their mental and emotional well-being
Social Support and Coping Strategies Among LGBTQIA+ Cancer Patients
https://www.facingourrisk.org/research-clinical-trials/study/303/social-support-and-coping-strategies-among-lgbtqia-cancer-patients
Surveys, Registries, Interviews
This study explores how different levels of support systems influence coping strategies among LGBTQIA+ cancer patients
FORCE Survey for People at Increased Risk for Colorectal, Pancreatic or Prostate Cancer
https://www.facingourrisk.org/research-clinical-trials/study/287/survey-for-people-at-increased-risk-for-breast-or-gynecologic-cancer-due-to-an-inherited-mutation
Surveys, Registries, Interviews
Survey for people at high risk for Colorectal, Pancreatic or Prostate Cancer
PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness
https://www.facingourrisk.org/research-clinical-trials/study/149/promise-registry-a-prostate-cancer-registry-of-outcomes-and-germline-mutations-for-improved-survival-and-treatment-effectiveness
Clinicaltrials.gov identifier:
NCT04995198 (https://clinicaltrials.gov/show/NCT04995198)
Surveys, Registries, Interviews
A screening registry for people diagnosed with prostate cancer
Denosumab for Breast Cancer Risk Reduction in Women With an Inherited BRCA1 Mutation (The Breast Cancer Prevention Study)
https://www.facingourrisk.org/research-clinical-trials/study/196/denosumab-for-breast-cancer-risk-reduction-in-women-with-an-inherited-brca1-mutation-the-breast-cancer-prevention-study
Clinicaltrials.gov identifier:
NCT04711109 (https://clinicaltrials.gov/show/NCT04711109)
Prevention
Prevention study enrolling women ages 25-55 with a BRCA1 mutation
Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/304/olaparib-with-cediranib-or-ceralasertib-for-people-with-advanced-or-metastatic-breast-cancer-and-with-a-brca1-or-brca2-mutation
Clinicaltrials.gov identifier:
NCT04090567 (https://clinicaltrials.gov/show/NCT04090567)
Treatment
This study will examine how Olaparib in combination with the drugs Cediranib or Ceralasertib works for patients with advanced breast cancer who have BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor
A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)
https://www.facingourrisk.org/research-clinical-trials/study/101/a-study-to-compare-two-surgical-procedures-in-women-with-brca1-mutations-to-assess-reduced-risk-of-ovarian-cancer-sorock
Clinicaltrials.gov identifier:
NCT04251052 (https://clinicaltrials.gov/show/NCT04251052)
Prevention
Ovarian cancer prevention for women with a BRCA1 mutation who still have their ovaries
PATROL Study: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease
https://www.facingourrisk.org/research-clinical-trials/study/291/patrol-study-prostate-cancer-screening-for-people-at-genetic-risk-for-aggressive-disease
Clinicaltrials.gov identifier:
NCT04472338 (https://clinicaltrials.gov/show/NCT04472338)
Prevention
Screening study for people with a mutation linked to prostate cancer risk
Combining the Immunotherapy Dostarlimab and PARP Inhibitor Niraparib for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with an Inherited or Tumor BRCA Mutation
https://www.facingourrisk.org/research-clinical-trials/study/231/immunotherapy-and-parp-inhibitor-for-advanced-or-metastatic-breast-ovarian-or-pancreatic-cancer-with-a-brca-mutation
Clinicaltrials.gov identifier:
NCT04673448 (https://clinicaltrials.gov/show/NCT04673448)
Treatment
Treatment study for people with advanced breast, ovarian or pancreatic cancer and an inherited or tumor BRCA mutation
Pancreatic Cancer Screening Study (CAPS5)
https://www.facingourrisk.org/research-clinical-trials/study/222/pancreatic-cancer-screening-studycaps5
Clinicaltrials.gov identifier:
NCT02000089 (https://clinicaltrials.gov/show/NCT02000089)
Prevention
Screening study for people at high risk for pancreatic cancer
Lynch Syndrome Vaccine Study
https://www.facingourrisk.org/research-clinical-trials/study/273/testing-a-combination-of-vaccines-for-cancer-prevention-in-lynch-syndrome
Clinicaltrials.gov identifier:
NCT05419011 (https://clinicaltrials.gov/show/NCT05419011)
Prevention
Testing A Combination Of Vaccines For Cancer Prevention In Lynch Syndrome
Cancer Prevention Vaccine (Nous-209) for People with Lynch Syndrome
https://www.facingourrisk.org/research-clinical-trials/study/278/cancer-prevention-vaccine-nous-209-for-people-with-lynch-syndrome
Clinicaltrials.gov identifier:
NCT05078866 (https://clinicaltrials.gov/show/NCT05078866)
Prevention
Prevention study for people with Lynch syndrome
Registry to Discover New Treatments and Developmental Processes of Colorectal and Endometrial Cancer in Patients with Hereditary Cancer
https://www.facingourrisk.org/research-clinical-trials/study/301/registry-to-discover-new-treatments-and-developmental-processes-of-colorectal-and-endometrial-cancer-in-patients-with-hereditary-cancer
Clinicaltrials.gov identifier:
NCT06096688 (https://clinicaltrials.gov/show/NCT06096688)
Surveys, Registries, Interviews
Study to collect and save data, cancer samples, and cancer family health histories from people who screen for colorectal endometrial cancer
The Phoenix Trial: Cemiplimab for Patients with Localized dMMR Colon Cancer
https://www.facingourrisk.org/research-clinical-trials/study/299/the-phoenix-trial-cemiplimab-for-patients-with-localized-dmmr-colon-cancer
Clinicaltrials.gov identifier:
NCT05961709 (https://clinicaltrials.gov/show/NCT05961709)
Treatment
This study will examine how well Cemiplimab works for patients with localized colon cancer who have dMMR
ShareForCures: Susan G. Komen's People-Powered, Data-Driven Breast Cancer Research Registry
https://www.facingourrisk.org/research-clinical-trials/study/295/shareforcures-susan-g-komens-people-powered-data-driven-breast-cancer-research-registry
Clinicaltrials.gov identifier:
NCT05654246 (https://clinicaltrials.gov/show/NCT05654246)
Surveys, Registries, Interviews
Registry for anyone diagnosed with breast cancer
A Pilot Study Investigating the Views of Key Stakeholders on Somatic and Germline Cancer Testing
https://www.facingourrisk.org/research-clinical-trials/study/298/individuals-views-on-somatic-and-germline-testing
Surveys, Registries, Interviews
This is a survey research study enrolling people with a history of cancer, cancer genetic testing, and an inherited mutation or variant of uncertain significance (VUS) in a hereditary cancer gene
The Risk Factor Analysis of Hereditary Breast and Ovarian Cancer In Women with BRCA1, BRCA2 or PALB2 Mutations
https://www.facingourrisk.org/research-clinical-trials/study/120/the-risk-factor-analysis-of-hereditary-breast-and-ovarian-cancer-in-women-with-brca1-brca2-or-palb2-mutations
Surveys, Registries, Interviews
Testing a Vaccine for Treating or Preventing Triple-Negative Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/285/treatment-study-for-people-with-stage-2-or-3-triple-negative-breast-cancer-at-high-risk-for-recurrence
Clinicaltrials.gov identifier:
NCT04674306 (https://clinicaltrials.gov/show/NCT04674306)
Treatment
Treatment study for people with stage 2 or 3 triple-negative breast cancer at high risk for recurrence.
A Survey on Options for Managing Cancer Risk Among Women with a BRCA1 or BRCA2 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/119/a-survey-on-options-for-managing-cancer-risk-among-women-with-a-brca1-or-brca2-mutation
Surveys, Registries, Interviews
Interviews with Young Women with a BRCA Mutation About Their Breast Cancer Risk Management Experiences
https://www.facingourrisk.org/research-clinical-trials/study/297/interviews-with-young-women-with-a-brca-mutation-about-their-breast-cancer-risk-management-experiences
Surveys, Registries, Interviews
Young women with a BRCA mutation
High Dose Testosterone Treatment for People with Metastatic Prostate Cancer and an ATM, CDK12 or CHEK2 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/294/high-dose-testosterone-treatment-for-people-with-metastatic-prostate-cancer-and-an-atm-cdk12-or-chek2mutation
Clinicaltrials.gov identifier:
NCT05011383 (https://clinicaltrials.gov/show/NCT05011383)
Treatment
People who have metastatic castration-resistant prostate cancer with an ATM, CDK12, or CHEK2 mutation
Study of a New Treatment Called TNG348 in People with Advanced or Metastatic Cancer and with a BRCA1 or BRCA2 Mutation or HRD Positive Tumor
https://www.facingourrisk.org/research-clinical-trials/study/296/study-of-a-new-treatment-called-tng348-in-people-with-advanced-or-metastatic-cancer-and-with-a-brca1-or-brca2-mutation-or-hrd-positive-tumor
Clinicaltrials.gov identifier:
NCT06065059 (https://clinicaltrials.gov/show/NCT06065059)
Treatment
Treatment for patients who have advanced breast, ovarian, pancreatic, and prostate cancer and a BRCA1 or BRCA2 mutation or have an HRD positive tumor
Roadmap to Parenthood: A Study about Fertility and Family-Building After Cancer
https://www.facingourrisk.org/research-clinical-trials/study/302/roadmap-to-parenthood-a-study-about-fertility-and-family-building-after-cancer
Clinicaltrials.gov identifier:
NCT06050135 (https://clinicaltrials.gov/show/NCT06050135)
Surveys, Registries, Interviews
Roadmap to Parenthood is a remote, survey-based study. Eligible participants must be aged 18-45, assigned female at birth, and history of a cancer diagnosis
Comparing Screening Methods for Detection of Early-Stage Gastric Cancer in People with a CHD1 Genetic Mutation
https://www.facingourrisk.org/research-clinical-trials/study/293/comparing-screening-methods-for-detection-of-early-stage-gastric-cancer-in-people-with-a-chd1-genetic-mutation
Clinicaltrials.gov identifier:
NCT04535414 (https://clinicaltrials.gov/show/NCT04535414)
Prevention
Gastric cancer screening study for people with a CHD1 inherited mutation
Screening Study for Men at High Genetic Risk for Prostate Cancer
https://www.facingourrisk.org/research-clinical-trials/study/72/men-at-high-genetic-risk-for-prostate-cancer
Clinicaltrials.gov identifier:
NCT03805919 (https://clinicaltrials.gov/show/NCT03805919)
Prevention
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation
Carboplatin Chemotherapy before Surgery for Patients with High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
https://www.facingourrisk.org/research-clinical-trials/study/286/swog-s2210-carboplatin-chemotherapy-before-surgery-for-patients-with-high-risk-prostate-cancer-and-an-inherited-brca1-or-brca2-gene-mutation
Clinicaltrials.gov identifier:
NCT05806515 (https://clinicaltrials.gov/show/NCT05806515)
Treatment
Treatment before surgery for people with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation
Study of a New Immunotherapy Treatment Called NC410 in People with Different Types of Advanced or Metastatic Cancers
https://www.facingourrisk.org/research-clinical-trials/study/251/study-of-an-immunotherapy-treatment-in-individuals-with-advanced-or-metastatic-solid-tumors
Clinicaltrials.gov identifier:
NCT05572684 (https://clinicaltrials.gov/show/NCT05572684)
Treatment
People with advanced or metastatic colorectal, endometrial, ovarian, stomach, esophageal or other cancers
A Study of the Drug REC-4881 For Treating People with Advanced Cancers with an APC or AXIN1 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/290/a-study-of-the-drug-rec-4881-for-treating-people-with-advanced-cancers-with-an-apc-or-axin1-mutation
Clinicaltrials.gov identifier:
NCT06005974 (https://clinicaltrials.gov/show/NCT06005974)
Treatment
Treatment study for people with advanced cancer with an APC or AXIN1 mutation
Studying a Combination of Three Drugs to Treat Previously Untreated Metastatic Colorectal Cancer which Is MSI-High and Has a BRAF V600E Mutation
https://www.facingourrisk.org/research-clinical-trials/study/252/comparing-three-drugs-in-patients-with-metastatic-colorectal-cancer-who-have-not-had-prior-treatment
Clinicaltrials.gov identifier:
NCT05217446 (https://clinicaltrials.gov/show/NCT05217446)
Treatment
Study for metastatic colorectal cancer that has not yet been treated
Testing the Safety And Action of the Investigational Drug REC-4881 in People With Familial Adenomatous Polyposis (FAP) (TUPELO Study)
https://www.facingourrisk.org/research-clinical-trials/study/288/testing-the-safety-and-action-of-the-investigational-drug-rec-4881-in-people-with-familial-adenomatous-polyposis-fap
Clinicaltrials.gov identifier:
NCT05552755 (https://clinicaltrials.gov/show/NCT05552755)
Prevention
Prevention study for people with an APC mutation and FAP who have had colectomy surgery
Using ctDNA Blood Test for Earlier Detection and Treatment of Recurrence or Spread after Treatment for Stage 3 Colon Cancer
https://www.facingourrisk.org/research-clinical-trials/study/283/using-ctdna-for-earlier-detection-and-treatment-of-recurrence-or-spread-after-treatment-for-stage-3-colon-cancer
Clinicaltrials.gov identifier:
NCT03803553 (https://clinicaltrials.gov/show/NCT03803553)
Treatment
Monitoring and treatment study for people who completed treatment for stage 3 colon cancer
Exploring How People of Caribbean Descent Share Information About Their Genetic Mutations with Family Members
https://www.facingourrisk.org/research-clinical-trials/study/275/exploring-how-people-of-caribbean-descent-share-information-about-their-genetic-mutations-with-their-family-members
Surveys, Registries, Interviews
Survey and interview for people of Caribbean descent who tested positive for a genetic mutation linked to cancer.
Comparing a Combination of Drugs for Treatment of HER2-positive Colorectal Cancer as First Line Treatment in the Metastatic Setting
https://www.facingourrisk.org/research-clinical-trials/study/274/treatment-of-her2-positive-colorectal-cancer-as-first-line-treatment-in-the-metastatic-setting
Clinicaltrials.gov identifier:
NCT05253651 (https://clinicaltrials.gov/show/NCT05253651)
Treatment
People with HER2-positive colorectal cancer who have not yet received treatment in the metastatic setting
Study of Colorectal Cancer and Genetics in Hispanic and Latino People (ENLACE Study)
https://www.facingourrisk.org/research-clinical-trials/study/276/study-of-colorectal-cancer-and-genetics-in-hispanic-and-latino-people-enlace-study
Treatment
Hispanic and Latino people diagnosed with colorectal cancer
Testing a Vaccine for Preventing or Treating Triple-Negative Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/284/testing-a-vaccine-for-treating-or-preventing-triple-negative-breast-cancer
Clinicaltrials.gov identifier:
NCT04674306 (https://clinicaltrials.gov/show/NCT04674306)
Prevention
Prevention study for people with a BRCA1, BRCA2 or PALB2 inherited mutation who are planning to undergo risk-reducing mastectomy.
Pancreatic Cancer Early Detection for People at High Risk
https://www.facingourrisk.org/research-clinical-trials/study/227/pancreatic-cancer-early-detection-for-people-at-high-risk
Clinicaltrials.gov identifier:
NCT04970056 (https://clinicaltrials.gov/show/NCT04970056)
Prevention
Registry and biobank for high risk people undergoing pancreatic cancer screening
Young, Empowered & Strong: Web-Based Symptom Monitoring and Self-Management for Young Adult Breast Cancer Survivors (YES Study)
https://www.facingourrisk.org/research-clinical-trials/study/199/young-empowered-strong-web-based-symptom-monitoring-and-self-management-for-young-adult-breast-cancer-survivors
Clinicaltrials.gov identifier:
NCT04906200 (https://clinicaltrials.gov/show/NCT04906200)
Quality of Life
Women diagnosed with breast cancer between the ages of 15-39
Collecting Blood and Stool Samples to Detect Colorectal Cancer or Precancerous Polyps in Lynch Syndrome Patients, CORAL Study
https://www.facingourrisk.org/research-clinical-trials/study/256/early-detection-of-colorectal-cancer-for-people-with-lynch-syndrome
Clinicaltrials.gov identifier:
NCT05410977 (https://clinicaltrials.gov/show/NCT05410977)
Prevention
People with Lynch Syndrome at risk for colon cancer
Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)
https://www.facingourrisk.org/research-clinical-trials/study/282/study-of-the-parp-inhibitor-azd9574-alone-and-combined-with-other-cancer-medicines-to-treat-people-with-advanced-solid-cancers-certis1-study
Clinicaltrials.gov identifier:
NCT05417594 (https://clinicaltrials.gov/show/NCT05417594)
Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas
The WISDOM Study: Women Informed to Screen Depending on Measures of Risk
https://www.facingourrisk.org/research-clinical-trials/study/45/wisdom-study
Clinicaltrials.gov identifier:
NCT02620852 (https://clinicaltrials.gov/show/NCT02620852)
Prevention
Study to Determine if Breast Cancer Screening can be Made Better by Personalizing Each Woman’s Mammogram Schedule
LIVING WELL: A Web-Based Program to Improve Quality of Life in Ovarian Cancer Survivors
https://www.facingourrisk.org/research-clinical-trials/study/270/living-well-a-web-based-program-to-improve-quality-of-life-in-ovarian-cancer-survivors
Clinicaltrials.gov identifier:
NCT04533763 (https://clinicaltrials.gov/show/NCT04533763)
Quality of Life
A research program offering mindfulness, coping, and healthy lifestyle skills for ovarian cancer survivors.
MRI Screening in Men at High Risk of Developing Prostate Cancer
https://www.facingourrisk.org/research-clinical-trials/study/260/screening-in-men-at-high-risk-of-developing-prostate-cancer
Clinicaltrials.gov identifier:
NCT05608694 (https://clinicaltrials.gov/show/NCT05608694)
Prevention
Screening using MRI for men at risk of developing prostate cancer
My Best GI Eating Study
https://www.facingourrisk.org/research-clinical-trials/study/258/my-best-gi-eating-study
Clinicaltrials.gov identifier:
NCT05396846 (https://clinicaltrials.gov/show/NCT05396846)
Prevention
Diet and weight loss study for people who are overweight and at increased risk of colorectal cancer
Intimacy and Self-Esteem Among Sexual and Gender Minority Cancer Survivors (RISE-SGM)
https://www.facingourrisk.org/research-clinical-trials/study/265/an-interview-about-intimacy-and-self-esteem-for-sexual-and-gender-minority-cancer-survivors
Surveys, Registries, Interviews
A one-time interview study to explore experiences with sexual functioning, sexual relationships, sexual self-concept, and self-esteem of 18-39-year-old sexual and/or gender minority cancer survivors
Studying People and Families Affected by Li-Fraumeni Syndrome (TP53 Mutation )
https://www.facingourrisk.org/research-clinical-trials/study/267/observing-people-who-have-li-fraumeni-syndrome-tp53-genetic-mutation
Clinicaltrials.gov identifier:
NCT01443468 (https://clinicaltrials.gov/show/NCT01443468)
Surveys, Registries, Interviews
Registry for people with Li-Fraumeni syndrome (LFS) or from LFS families
Registry to Promote Health Equity for People of African Ancestry with Breast or Prostate Cancer
https://www.facingourrisk.org/research-clinical-trials/study/277/registry-to-promote-health-equity-for-people-of-african-ancestry-with-breast-or-prostate-cancer
Clinicaltrials.gov identifier:
NCT05754658 (https://clinicaltrials.gov/show/NCT05754658)
Surveys, Registries, Interviews
This is a registry for people of African ancestry who have breast or prostate cancer
A Surveillance Program for Women at High Risk for Breast Cancer (CAPSBRACA)
https://www.facingourrisk.org/research-clinical-trials/study/271/a-surveillance-program-for-women-at-high-risk-for-breast-cancer-capsbraca
Clinicaltrials.gov identifier:
NCT03729115 (https://clinicaltrials.gov/show/NCT03729115)
Surveys, Registries, Interviews
Screening study for women at risk for breast cancer due to an inherited mutation or other risk factor
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women (TUBA/WISP II)
https://www.facingourrisk.org/research-clinical-trials/study/205/risk-reducing-salpingectomy-with-delayed-oophorectomy-as-an-alternative-to-risk-reducing-salpingo-oophorectomy-in-high-risk-women
Clinicaltrials.gov identifier:
NCT05287451 (https://clinicaltrials.gov/show/NCT05287451)
Prevention
Prevention study for women at high risk for ovarian cancer
Coaching for Family Caregivers of People with Advanced Cancer from Rural and Minority Communities
https://www.facingourrisk.org/research-clinical-trials/study/272/quality-of-life-study-for-caregivers-involving-in-person-or-telephone-coaching-sessions
Clinicaltrials.gov identifier:
NCT04318886 (https://clinicaltrials.gov/show/NCT04318886)
Quality of Life
Quality of life study for caregivers involving in-person or telephone coaching sessions
Testing the Drug Obeticholic Acid for Familial Adenomatous Polyposis
https://www.facingourrisk.org/research-clinical-trials/study/289/testing-the-drug-obeticholic-acid-for-familial-adenomatous-polyposis
Clinicaltrials.gov identifier:
NCT05223036 (https://clinicaltrials.gov/show/NCT05223036)
Prevention
Prevention study for people with an APC mutation and FAP or AFAP who have polyps in remaining tissue after colectomy surgery
A Randomized Study of Robotic-Assisted Nipple Sparing Mastectomy vs. Standard Surgery Nipple Sparing Mastectomy for Early Stage Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/263/a-randomized-study-of-robotic-assisted-nipple-sparing-mastectomy-vs-open-surgery-nipple-sparing-mastectomy-for-early-stage-breast-cancer
Clinicaltrials.gov identifier:
NCT05720039 (https://clinicaltrials.gov/show/NCT05720039)
Treatment
Nipple sparing mastectomy with reconstruction for women with early-stage breast cancer
Testing a Vaccine for Cancer Prevention in People with a BRCA1 or BRCA2 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/172/testing-a-vaccine-for-cancer-prevention-in-people-with-a-brca1-or-brca2-mutation
Clinicaltrials.gov identifier:
NCT04367675 (https://clinicaltrials.gov/show/NCT04367675)
Prevention
People with a BRCA1 or BRCA2 mutation
Survey about Motivations and Barriers to Talking with Family Members about Inherited Cancer Risk
https://www.facingourrisk.org/research-clinical-trials/study/280/survey-about-goals-of-inherited-cancer-risk-disclosure-in-families-with-an-inherited-gene-mutation
Surveys, Registries, Interviews
Survey for people with an inherited gene mutation
A Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer
https://www.facingourrisk.org/research-clinical-trials/study/245/a-study-of-different-targeted-therapies-for-patients-with-recurrent-or-persistent-endometrial-cancer
Clinicaltrials.gov identifier:
NCT04486352 (https://clinicaltrials.gov/show/NCT04486352)
Treatment
This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent endometrial cancer.
A Study Comparing Two Anti-inflammatory Medications Naproxen or Aspirin for Cancer Prevention in Lynch Syndrome
https://www.facingourrisk.org/research-clinical-trials/study/281/studying-the-use-of-naproxen-and-aspirin-for-cancer-prevention-in-people-with-lynch-syndrome
Clinicaltrials.gov identifier:
NCT05411718 (https://clinicaltrials.gov/show/NCT05411718)
Prevention
Prevention study for people with Lynch syndrome
Kindred Study
https://www.facingourrisk.org/research-clinical-trials/study/255/kindred
Surveys, Registries, Interviews
Interviews with African American people who tested positive for a genetic mutation
Testing an Immunotherapy, Pembrolizumab, in Patients With Advanced Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/234/testing-an-immunotherapy-in-patients-with-advanced-solid-tumors
Clinicaltrials.gov identifier:
NCT02628067 (https://clinicaltrials.gov/show/NCT02628067)
Treatment
Treatment study for people with advanced cancers
TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer
https://www.facingourrisk.org/research-clinical-trials/study/262/tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer
Clinicaltrials.gov identifier:
NCT02693535 (https://clinicaltrials.gov/show/NCT02693535)
Treatment
Cancer treatment study for people with advanced solid tumors
Self -Perception and Intimacy After the Cancer Experience (SPICE)
https://www.facingourrisk.org/research-clinical-trials/study/247/self-perception-and-intimacy-after-the-cancer-experience-spice
Surveys, Registries, Interviews
Online survey for cancer survivors ages 18-39 years old about sexual health
Metastatic Castration Resistant Prostate Cancer Clinical Trial
https://www.facingourrisk.org/research-clinical-trials/study/240/metastatic-castration-resistant-prostate-cancer-clinical-trial
Clinicaltrials.gov identifier:
NCT03460977 (https://clinicaltrials.gov/show/NCT03460977)
Treatment
This clinical trial is studying a potential treatment for men with metastatic castration resistant prostate cancer.
Investigating the Use of Self-Acupressure for Fatigue in Ovarian Cancer Survivors
https://www.facingourrisk.org/research-clinical-trials/study/242/investigating-the-use-of-self-acupressure-for-fatigue-in-ovarian-cancer-survivors
Clinicaltrials.gov identifier:
NCT03763838 (https://clinicaltrials.gov/show/NCT03763838)
Quality of Life
University of Michigan researchers are investigating the use of self-acupressure for fatigue in ovarian cancer survivors.
Survey for Women at High Risk for Breast Cancer on Knowledge and Perspectives about Breast Cancer Risk Factors and Screening
https://www.facingourrisk.org/research-clinical-trials/study/238/survey-for-women-at-high-risk-for-breast-cancer-on-knowledge-and-perspectives-about-breast-cancer-risk-factors-and-screening
Surveys, Registries, Interviews
Online survey for women with an ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, RAD51C, RAD51D, STK11 or TP53 inherited mutation.
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
https://www.facingourrisk.org/research-clinical-trials/study/175/niraparib-before-surgery-in-treating-patients-with-high-risk-localized-prostate-cancer-and-dna-damage-response-defects
Clinicaltrials.gov identifier:
NCT04030559 (https://clinicaltrials.gov/show/NCT04030559)
Treatment
High-risk localized prostate cancer
Testing Immunotherapy Treatments for Recurrent Endometrial Cancer
https://www.facingourrisk.org/research-clinical-trials/study/253/testing-cancer-treatments-in-recurrent-endometrial-cancer
Clinicaltrials.gov identifier:
NCT05112601 (https://clinicaltrials.gov/show/NCT05112601)
Treatment
Treatment study for people with endometrial cancer that has returned
Opening the Conversation
https://www.facingourrisk.org/research-clinical-trials/study/228/opening-the-conversation
Clinicaltrials.gov identifier:
NCT04806724 (https://clinicaltrials.gov/show/NCT04806724)
Quality of Life
Online communication program for breast and gynecologic cancer survivors and their partners
Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib
https://www.facingourrisk.org/research-clinical-trials/study/230/treating-metastatic-solid-tumors-with-an-inherited-or-acquired-gene-mutation-using-the-parp-inhibitor-talazoparib
Clinicaltrials.gov identifier:
NCT04550494 (https://clinicaltrials.gov/show/NCT04550494)
Treatment
Treatment study for people with advanced solid tumors
Combined Pembrolizumab & Quavonlimab (MK-1308A) Versus Other Treatments in People With MSI-High or dMMR Stage IV Colorectal Cancer
https://www.facingourrisk.org/research-clinical-trials/study/181/combined-pembrolizumab-quavonlimab-mk-1308a-versus-other-treatments-in-people-with-msi-high-or-dmmr-stage-iv-colorectal-cancer
Clinicaltrials.gov identifier:
NCT04895722 (https://clinicaltrials.gov/show/NCT04895722)
Treatment
Stage 4 colorectal cancer
Survey for People Diagnosed with Breast Cancer to Provide Feedback on a New Type of Clinical Trial
https://www.facingourrisk.org/research-clinical-trials/study/226/survey-for-people-diagnosed-with-breast-cancer-to-provide-feedback-on-a-new-type-of-clinical-trial
Surveys, Registries, Interviews
Survey for people diagnosed with stage 0 - stage 3 breast cancer
Combination ATR inhibitor and PARP Inhibitor in Recurrent Ovarian Cancer (CAPRI)
https://www.facingourrisk.org/research-clinical-trials/study/156/combination-atr-inhibitor-and-parp-inhibitor-in-recurrent-ovarian-cancer-capri
Clinicaltrials.gov identifier:
NCT03462342 (https://clinicaltrials.gov/show/NCT03462342)
Treatment
Recurrent ovarian cancer
Effect of Acupuncture on Memory and Thinking Difficulties after Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/219/effect-of-acupuncture-on-memory-and-thinking-difficulties-after-breast-cancer
Clinicaltrials.gov identifier:
NCT04837820 (https://clinicaltrials.gov/show/NCT04837820)
Quality of Life
Acupuncture study for people with memory issues who completed treatment for stage 0-3 breast cancer
Restoring Sensation after DIEP Flap Reconstruction
https://www.facingourrisk.org/research-clinical-trials/study/217/restoring-sensation-after-diep-flap-reconstruction
Clinicaltrials.gov identifier:
NCT04533373 (https://clinicaltrials.gov/show/NCT04533373)
Prevention
Study for people undergoing DIEP flap reconstruction
A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (APOLLO)
https://www.facingourrisk.org/research-clinical-trials/study/140/olaparib-or-placebo-in-patients-with-surgically-removed-pancreatic-cancer-who-have-a-brca1-brca2-or-palb2-mutation
Clinicaltrials.gov identifier:
NCT04858334 (https://clinicaltrials.gov/show/NCT04858334)
Treatment
Tools To Be Fit: Tools to Improve Nutrition and Physical Activity for Cancer Survivors
https://www.facingourrisk.org/research-clinical-trials/study/171/tools-to-be-fit-tools-to-improve-nutrition-and-physical-activity-for-colorectal-cancer-survivors
Clinicaltrials.gov identifier:
NCT05056077 (https://clinicaltrials.gov/show/NCT05056077)
Quality of Life
Bladder, breast, colon, endometrial, kidney (renal cell carcinoma), ovarian, prostate, or rectal cancer
Factors Influencing Disparities in Quality of Life among People of Color Affected by Cancer
https://www.facingourrisk.org/research-clinical-trials/study/223/factors-influencing-disparities-in-quality-of-life-among-people-of-color-affected-by-cancer
Surveys, Registries, Interviews
Survey for people of color who have completed treatment for cancer
Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)
https://www.facingourrisk.org/research-clinical-trials/study/180/prostate-cancer-genetic-risk-evaluation-and-screening-study-progress
Clinicaltrials.gov identifier:
NCT05129605 (https://clinicaltrials.gov/show/NCT05129605)
Prevention
People at high risk for prostate cancer due to an inherited mutation
NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/204/nuv-868-alone-and-in-combination-with-parp-inhibitors-in-patients-with-advanced-solid-tumors
Clinicaltrials.gov identifier:
NCT05252390 (https://clinicaltrials.gov/show/NCT05252390)
Treatment
Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer
Opening the Conversation Study
https://www.facingourrisk.org/research-clinical-trials/study/214/opening-the-conversation-study
Clinicaltrials.gov identifier:
NCT04806724 (https://clinicaltrials.gov/show/NCT04806724)
Quality of Life
Videoconference sessions that address cancer related concerns for couples
Study of Physical Activity at Home for Relief from Neuropathy Caused by Taxanes in People with Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/220/physical-activity-at-home-for-relief-from-neuropathy-caused-by-taxanes-in-people-with-breast-cancer
Clinicaltrials.gov identifier:
NCT04621721 (https://clinicaltrials.gov/show/NCT04621721)
Quality of Life
Quality of life study for breast cancer patients experiencing neuropathy from chemotherapy
Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA)
https://www.facingourrisk.org/research-clinical-trials/study/210/treating-metastatic-prostate-cancer-with-chemotherapy-or-parp-inhibitor-in-people-with-mutations-cobra
Clinicaltrials.gov identifier:
NCT04038502 (https://clinicaltrials.gov/show/NCT04038502)
Treatment
Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L
Blood Markers of Early Pancreas Cancer
https://www.facingourrisk.org/research-clinical-trials/study/141/blood-markers-of-early-pancreas-cancer
Clinicaltrials.gov identifier:
NCT03568630 (https://clinicaltrials.gov/show/NCT03568630)
Prevention
Observational study for people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk.
Helping Latinas Understand Their Risk for Breast Cancer and Get Breast Cancer Care
https://www.facingourrisk.org/research-clinical-trials/study/250/helping-latinas-understand-their-risk-for-breast-cancer-and-get-breast-cancer-care
Clinicaltrials.gov identifier:
NCT05483283 (https://clinicaltrials.gov/show/NCT05483283)
Prevention
Latinas with a high risk of breast cancer
Upright MRI for Prostate Cancer Screening
https://www.facingourrisk.org/research-clinical-trials/study/259/upright-mri-for-prostate-cancer-screening
Clinicaltrials.gov identifier:
NCT03474913 (https://clinicaltrials.gov/show/NCT03474913)
Prevention
Screening for prostate cancer using upright MRI
Study of Oral Drug Bazedoxifene Plus Conjugated Estrogens for Treating Hot Flashes in Women at High Risk for Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/218/bazedoxifene-plus-conjugated-estrogens-for-hot-flashes-in-women-at-high-risk-for-breast-cancer
Clinicaltrials.gov identifier:
NCT04821141 (https://clinicaltrials.gov/show/NCT04821141)
Quality of Life
Women at high risk for breast cancer due to ATM, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, STK11, P53 or PTEN mutation who have hot flashes
Research Opportunity for Previvors and their Romantic Partners
https://www.facingourrisk.org/research-clinical-trials/study/207/research-opportunity-for-previvors-and-their-romantic-partners
Surveys, Registries, Interviews
Interview for people with inherited mutations who had risk-reducing mastectomy and their partners
BRCA 1 and 2: Interviews on Genetic Testing and Individual Experiences
https://www.facingourrisk.org/research-clinical-trials/study/169/brca-1-and-2-interviews-on-genetic-testing-and-individual-experiences
Surveys, Registries, Interviews
People with or without cancer who have had or are considering BRCA testing
Cancer Experience Registry
https://www.facingourrisk.org/research-clinical-trials/study/248/cancer-experience-registry
Surveys, Registries, Interviews
Online survey for patients and caregivers focusing on multiple aspects of cancer
SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells
https://www.facingourrisk.org/research-clinical-trials/study/117/sharon-a-clinical-trial-for-metastatic-cancer-with-an-inherited-brca-or-palb2-mutation-using-chemotherapy-and-patients-own-stem-cells
Clinicaltrials.gov identifier:
NCT04150042 (https://clinicaltrials.gov/show/NCT04150042)
Treatment
Advanced pancreatic cancer or stage 4 breast cancer in people with a BRCA1 or BRCA2 mutation
IGNITE-TX - Identifying Individuals for Genetic Testing for Familial Cancer
https://www.facingourrisk.org/research-clinical-trials/study/266/helping-people-with-a-genetic-mutation-in-brca1-brca2-or-lynch-syndrome-talk-to-their-family-members-about-their-risk-for-cancer-and-find-the-best-way-to-get-family-members-tested
Clinicaltrials.gov identifier:
NCT05677048 (https://clinicaltrials.gov/show/NCT05677048)
Prevention
People with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome who have relatives who have not been tested
All of Us Research Program
https://www.facingourrisk.org/research-clinical-trials/study/197/all-of-us-research-program
Surveys, Registries, Interviews
Anyone age 18 or over
Treating Early-Stage HER2-Negative Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/158/treating-early-stage-breast-cancer-with-a-parp-inhibitor-niraparib-and-immunotherapy-dostarlimab-in-people-with-a-brca-or-palb2-mutation
Clinicaltrials.gov identifier:
NCT04584255 (https://clinicaltrials.gov/show/NCT04584255)
Treatment
Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation
Androgen Suppression With Abiraterone, Leuprolide, PARP Inhibitor and Stereotactic Radiotherapy in Prostate Cancer (ASCLEPIuS)
https://www.facingourrisk.org/research-clinical-trials/study/177/androgen-suppression-with-abiraterone-leuprolide-parp-inhibitor-and-stereotactic-radiotherapy-in-prostate-cancer-asclepius
Clinicaltrials.gov identifier:
NCT04194554 (https://clinicaltrials.gov/show/NCT04194554)
Treatment
Newly diagnosed prostate cancer grade group 3-5
Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)
https://www.facingourrisk.org/research-clinical-trials/study/176/investigational-parp-inhibitor-azd5305-alone-or-combined-with-other-anti-cancer-agents-in-people-with-advanced-solid-tumors-petra
Clinicaltrials.gov identifier:
NCT04644068 (https://clinicaltrials.gov/show/NCT04644068)
Treatment
Advanced ovarian, breast, prostate or pancreatic cancer
Inherited Cancer Registry (ICARE): Contribute to Research While Staying Informed
https://www.facingourrisk.org/research-clinical-trials/study/195/inherited-cancer-registry-icare-contribute-to-research-while-staying-informed
Clinicaltrials.gov identifier:
NCT03231891 (https://clinicaltrials.gov/show/NCT03231891)
Surveys, Registries, Interviews
People with an inherited mutation or cancer in the family
Adding Pembrolizumab to Olaparib to Treat Pancreatic Cancer in People with an Inherited BRCA Mutation
https://www.facingourrisk.org/research-clinical-trials/study/164/adding-pembrolizumab-to-olaparib-to-treat-pancreatic-cancer-in-people-with-an-inherited-brca-mutation
Clinicaltrials.gov identifier:
NCT04548752 (https://clinicaltrials.gov/show/NCT04548752)
Treatment
Metastatic pancreatic cancer and a BRCA1 or BRCA2 mutation
Retifanlimab (Immunotherapy) Alone or Combined with Other Therapies for Advanced Endometrial Cancer that Progressed on or after Platinum Chemotherapy (POD1UM-204)
https://www.facingourrisk.org/research-clinical-trials/study/165/retifanlimab-alone-or-with-other-agents-for-advanced-endometrial-cancer-that-progressed-with-platinum
Clinicaltrials.gov identifier:
NCT04463771 (https://clinicaltrials.gov/show/NCT04463771)
Treatment
Advanced endometrial cancer
Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/157/treatment-with-atr-inhibitor-for-advanced-or-metastatic-solid-tumors
Clinicaltrials.gov identifier:
NCT04657068 (https://clinicaltrials.gov/show/NCT04657068)
Treatment
Advanced solid tumors
Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor
https://www.facingourrisk.org/research-clinical-trials/study/151/nivolumab-and-relatlimab-in-advanced-msi-h-cancers-resistant-to-prior-pd-l1-inhibitor
Clinicaltrials.gov identifier:
NCT03607890 (https://clinicaltrials.gov/show/NCT03607890)
Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy
Developing a Test for the Detection of Ovarian Cancer
https://www.facingourrisk.org/research-clinical-trials/study/137/developing-a-test-for-the-detection-of-ovarian-cancer
Clinicaltrials.gov identifier:
NCT04794322 (https://clinicaltrials.gov/show/NCT04794322)
Prevention
Chemotherapy, Bevacizumab, and/or Atezolizumab for Patients With Deficient DNA Mismatch Repair (dMMR or MSI-H) Metastatic Colorectal Cancer, the COMMIT Study
https://www.facingourrisk.org/research-clinical-trials/study/126/chemotherapy-bevacizumab-andor-atezolizumab-for-dmmr-msi-h-metastatic-colorectal-cancer-commit-study
Clinicaltrials.gov identifier:
NCT02997228 (https://clinicaltrials.gov/show/NCT02997228)
Treatment
Preliminary Evaluation of Screening for Pancreatic Cancer in Patients with an Inherited Genetic Risk Due to a BRCA1, BRCA2, PALB2 or ATM Mutation
https://www.facingourrisk.org/research-clinical-trials/study/121/screening-for-pancreatic-cancer-in-patients-with-an-inherited-brca1-brca2-palb2-or-atm-mutation
Clinicaltrials.gov identifier:
NCT02478892 (https://clinicaltrials.gov/show/NCT02478892)
Prevention
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations
https://www.facingourrisk.org/research-clinical-trials/study/129/olaparib-in-treating-patients-with-metastatic-biliary-tract-cancer-with-aberrant-dna-repair-gene-mutations
Clinicaltrials.gov identifier:
NCT04042831 (https://clinicaltrials.gov/show/NCT04042831)
Treatment
Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families: MicroRNA Detection Study (MiDE)
https://www.facingourrisk.org/research-clinical-trials/study/138/validating-a-blood-test-for-early-ovarian-cancer-detection-in-high-risk-women-and-families
Prevention
Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW)
https://www.facingourrisk.org/research-clinical-trials/study/112/nivolumab-nivolumab-plus-ipilimumab-or-chemotherapy-for-microsatellite-instability-high-msi-h-metastatic-colorectal-cancer-checkmate-8hw
Clinicaltrials.gov identifier:
NCT04008030 (https://clinicaltrials.gov/show/NCT04008030)
Treatment
People with metastatic colorectal cancer that is MSI-High
Pembrolizumab and Olaparib for People With Metastatic Pancreatic Cancer with Homologous Recombination Deficiency or Exceptional Response to Platinum Chemotherapy
https://www.facingourrisk.org/research-clinical-trials/study/127/pembrolizumab-and-olaparib-for-metastatic-pancreatic-cancer-with-homologous-recombination-deficiency-or-exceptional-response-to-platinum-chemotherapy
Clinicaltrials.gov identifier:
NCT04666740 (https://clinicaltrials.gov/show/NCT04666740)
Treatment
Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations
https://www.facingourrisk.org/research-clinical-trials/study/109/blood-tests-to-measure-ovarian-reserves-in-women-with-a-brca-mutation-or-women-treated-for-early-stage-breast-cancer
Clinicaltrials.gov identifier:
NCT00823654 (https://clinicaltrials.gov/show/NCT00823654)
Prevention
Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations
https://www.facingourrisk.org/research-clinical-trials/study/100/talazoparib-for-people-with-metastatic-breast-cancer-who-have-acquired-somatic-brca-mutations
Clinicaltrials.gov identifier:
NCT03990896 (https://clinicaltrials.gov/show/NCT03990896)
Treatment
A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast, Ovarian, Prostate and Pancreatic Cancer Patients
https://www.facingourrisk.org/research-clinical-trials/study/102/a-randomized-study-of-an-ehealth-delivery-alternative-for-cancer-genetic-testing-for-hereditary-predisposition-in-metastatic-breast-ovarian-prostate-and-pancreatic-cancer-patients-e-reach
Clinicaltrials.gov identifier:
NCT04353973 (https://clinicaltrials.gov/show/NCT04353973)
Treatment
Metastatic Prostate Cancer Project
https://www.facingourrisk.org/research-clinical-trials/study/70/metastatic-prostate-cancer-project
Surveys, Registries, Interviews
The Metastatic Breast Cancer Project
https://www.facingourrisk.org/research-clinical-trials/study/60/the-metastatic-breast-cancer-project
Surveys, Registries, Interviews
A Pancreatic Cancer Screening Study for High Risk Individuals
https://www.facingourrisk.org/research-clinical-trials/study/95/pancreatic-cancer-screening-study-for-high-risk-people
Clinicaltrials.gov identifier:
NCT03250078 (https://clinicaltrials.gov/show/NCT03250078)
Prevention
RANKL Inhibition With Denosumab on Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT)
https://www.facingourrisk.org/research-clinical-trials/study/93/denosumab-and-mammographic-density-in-premenopausal-women-with-dense-breasts-trident
Clinicaltrials.gov identifier:
NCT04067726 (https://clinicaltrials.gov/show/NCT04067726)
Prevention
Connect My Variant
https://www.facingourrisk.org/research-clinical-trials/study/90/connect-my-variant
Surveys, Registries, Interviews
Genomic Services Research Program Study for People with Unexpected Genetic Results
https://www.facingourrisk.org/research-clinical-trials/study/89/study-for-people-with-unexpected-genetic-results
Clinicaltrials.gov identifier:
NCT02595957 (https://clinicaltrials.gov/show/NCT02595957)
Prevention
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job (TEAMWork Study)
https://www.facingourrisk.org/research-clinical-trials/study/86/talking-to-employers-and-medical-staff-about-breast-cancer-treatment-and-your-job
Clinicaltrials.gov identifier:
NCT03572374 (https://clinicaltrials.gov/show/NCT03572374)
Quality of Life
Breast Cancer Treatment in Women with PALB2 Mutations
https://www.facingourrisk.org/research-clinical-trials/study/85/breast-cancer-treatment-in-women-with-palb2-mutations
Surveys, Registries, Interviews
Energetics and Lifestyle in Inherited Syndromes (ELLIE’s Study)
https://www.facingourrisk.org/research-clinical-trials/study/84/ellies-project
Quality of Life
Identification and Analysis of Families With Genetic Susceptibility To Cancer Registry
https://www.facingourrisk.org/research-clinical-trials/study/33/identification-and-analysis-of-families-with-genetic-susceptibility-to-cancer-registry
Surveys, Registries, Interviews
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.